Addex Therapeutics Balances Pipeline Progress and Cash Strain

Addex Therapeutics Ltd ((CH:ADXN)) has held its Q1 earnings call. Read on for the main highlights of the call.

TipRanks' Prime Week Sale - 70% Off

• Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
• Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.

Addex Therapeutics’ latest earnings call balanced upbeat scientific progress with stark funding realities. Management highlighted robust preclinical efficacy in its two lead programs and meaningful optionality from partnerships and equity stakes. However, limited cash, a short runway for unpartnered assets, and rising losses underscored considerable execution risk for investors tracking the story.

GABAB PAM Cough Program Shows Strong Preclinical Signal

Lead GABAB positive allosteric modulator “Compound A” delivered up to about 70% reduction in coughs in guinea pig models and more than 60% reduction in non‑human primates at 2 mg/kg. The compound also achieved sustained 40–60% cough reductions and better lung histology in an IPF‑like model, with no tolerance over seven days and a safety margin above 60‑fold, leaving IND‑enabling work ready to launch once funded.

Dipraglurant Repositioned for Post‑Stroke and TBI Recovery

Dipraglurant, an mGluR5 NAM, has been repurposed for post‑stroke and traumatic brain injury recovery after Addex regained rights and retained GMP material and a strong data package. Preclinical studies showed sustained gains in sensorimotor function and improved MRI connectivity when used alongside rehabilitation, with management preparing an imaging‑led stroke study backed by favorable tolerability and a solid patent position.

Indivior Collaboration Offers Significant Milestone Upside

Under its collaboration with Indivior, Addex has already seen a partner‑selected compound move through IND‑enabling work for substance use disorders. While timelines remain in Indivior’s control, Addex is eligible for up to $313 million in milestones plus high single‑ to low double‑digit royalties on future sales, representing a potentially transformative but contingent value driver.

Neurosterix Stake Advances Toward Value‑Inflection Events

Addex’s 20% equity holding in Neurosterix provides leveraged exposure to a growing neuroscience pipeline, led by M4 PAM candidate NTX‑53 now in Phase 1 with data expected in the third quarter of 2026. A backup M4 PAM and a first‑in‑class mGluR7 program add depth, and management emphasized both valuation upside and active inbound interest in the asset as possible monetization scenarios.

Cost Discipline Drives Lower Operating Loss

Operating loss in the first quarter of fiscal 2026 fell to CHF 0.5 million from CHF 0.6 million a year earlier, a reduction of roughly 16.7%. The improvement largely reflected lower outsourced R&D costs following the Neurosterix spinout, signaling tighter cost control even as the company maintains its core scientific capabilities.

Lean Cash Burn Extends Runway Post‑Spinout

Following a sharp reduction in spending, Addex ended the first quarter with around CHF 0.9 million in cash and subsequently raised approximately CHF 0.3 million through an at‑the‑market facility. Management said this supports operations into the fourth quarter of 2026 on a going‑concern basis, though it does not cover the cost of advancing unpartnered programs into clinical trials.

Funding Gap Blocks Progress of Unpartnered Pipeline

Despite the extended runway, the company’s roughly CHF 0.9 million cash balance at quarter‑end, down from CHF 1.6 million, leaves a clear shortfall for IND and clinical work on its own assets. Management stressed that both the GABAB cough candidate and Dipraglurant’s next steps hinge on securing additional capital or new partners, putting a near‑term ceiling on internal pipeline progress.

Rising Net Loss Amplified by Neurosterix Accounting

Net loss widened to CHF 1.7 million from CHF 1.5 million year on year, driven largely by Addex’s share of Neurosterix’s growing losses as that venture moves programs into the clinic. The equity‑method loss rose to CHF 1.3 million from CHF 0.8 million, meaning the spinout both provides upside exposure and exerts a material drag on the parent’s income statement.

Balance Sheet Shows Tight Working‑Capital Position

The company reported very small current assets of around CHF 25,000, mainly prepaid retirement benefits, against current liabilities of CHF 1.2 million, highlighting a constrained working‑capital profile. While non‑current assets include a CHF 3.5 million equity investment in Neurosterix, the near‑term liquidity picture remains tight until new funding is secured.

Perceived Valuation Gap in Neurosterix Equity Stake

Management argued that the market undervalues its 20% holding in Neurosterix, which was previously tied to a post‑money valuation near CHF 20 million versus Addex’s cited market cap around CHF 8 million. This perceived disconnect underscores latent asset value but also uncertainty on when and how a sale, financing event, or listing might crystallize returns for shareholders.

Guidance Highlights Cash Limits and Upcoming Catalysts

Guidance reaffirmed cash of roughly CHF 900,000–935,000 at the end of the first quarter plus CHF 300,000 raised in the second, ensuring operations into late 2026 but not unpartnered IND starts. Key milestones include Phase 1 data for Neurosterix’s NTX‑53 targeted in the third quarter, financing‑dependent IND work for the GABAB cough program, repositioning of Dipraglurant with optioned IP, and long‑dated upside from Indivior milestones and potential royalties.

Addex’s earnings call painted a picture of a company rich in scientific options but constrained by capital, forcing a selective, partnership‑driven strategy. Investors will be watching whether management can unlock value from Neurosterix and Indivior while securing funding to bring promising in‑house assets like Compound A and Dipraglurant into the clinic, where their preclinical promise will face its real test.